Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis.
about
Bottom-up modeling approach for the quantitative estimation of parameters in pathogen-host interactions.In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.D-arabinitol--a marker for invasive candidiasis.PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies.Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR.Towards a targeted, risk-based, antifungal strategy in neutropenic patients.Candida bracarensis bloodstream infection in an immunocompromised patient.Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.Prophylactic antifungal therapy in the intensive care unit.Therapy for fungal infections in leukemia.A strategy for managing fungal infections in haematopoietic stem cell transplantation.Emerging fungal infections among children: A review on its clinical manifestations, diagnosis, and prevention.Fungal infections: a growing threatEpidemiology and Prevention of Invasive Aspergillosis.Assessing risk factors for systemic fungal infections.Impaired gut function as risk factor for invasive candidiasis in neutropenic patients.Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients.Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients.A virtual infection model quantifies innate effector mechanisms and Candida albicans immune escape in human blood.Differential humoral response against alpha- and beta-linked mannose residues associated with tissue invasion by Candida albicans.Antifungal prophylaxis during neutropenia and immunodeficiencyDisseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Enterococcus faecium.Fluconazole for the treatment of candidiasis: 15 years experience.A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection.Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens.ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia.Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology.Diagnosis of invasive candidiasis in neutropenic children with cancer by determination of D-arabinitol/L-arabinitol ratios in urine.Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival.Retrospective analysis of yeast colonization and infections in paediatric bone marrow transplant recipients.Fungal infections in neutropenic patients. A 8-year prospective study.An autopsy study of systemic fungal infections in patients with hematologic malignancies.Clinical and laboratory diagnosis of invasive candida infection in neutropenic patients.Prevention and therapy of fungal infections in cancer patients. A review of recently published information.Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.
P2860
Q21131074-5A9A306D-8A73-4B56-89A9-0BE82D8EF980Q28367886-536AF2EB-9A2F-4C96-8702-6BCAF48E3B8BQ28379217-AEF2EC43-C86B-49C1-BF72-FE5C0930851FQ31372000-35EDC685-65F5-428C-8EAF-22A3F3875D3CQ31893406-DED0A753-13B8-4AE7-984B-6C6F84498B76Q33824206-669C7241-7E73-48DE-A457-B858B2730622Q33960914-FE7971F1-DEC5-4457-AC8B-ED93FAE6586FQ33964096-1C70EF6C-767E-4203-80A4-F80E34E3DCF8Q34022479-60E0DA7A-CE1A-4206-8741-C6513B24632CQ34140852-1D7F37A6-0826-4855-80DD-60132FC00AA0Q34166590-FF65830E-DAE3-4ECC-8FD0-41575701BC1FQ34205622-BF1BFF34-2338-43F0-B0BD-891DD2BBE170Q34214827-F4D9BD5D-87F0-4D2A-8468-4BEB7CF74B69Q34294925-09C18822-979F-4F44-91EC-2DB7D13F0217Q34373864-E73319FB-4F00-4F13-BAB8-153DF7C49370Q34404601-EC0E2505-F043-4031-87B8-90048F81CE9EQ34448527-6246E20A-5010-4E79-8CA1-D8F07513ADC7Q34517136-26DA63E0-1B9F-41E3-9D44-DADAEF6290F7Q34612183-2FBFF832-B7D5-4C11-9620-A66EC5797502Q34746953-E269EDDC-A80D-4468-962F-3D238D3DF46EQ34990441-169DC326-2CA5-43A1-8611-582133C4943BQ35105573-3F466771-8E53-43F7-B469-927EC6822215Q35229630-7CDE5569-D937-4B00-AC29-B3F6DE0D05ADQ35374928-F58DAE3B-9FF3-4ED5-8D6D-EA2C692C5815Q35551863-E335369A-0BA0-436E-B1F0-C69E433350FDQ35917407-C2BE19C0-BE14-47EA-986B-AD3E91FB0F10Q35987403-33DE7B40-F5B8-43D1-B5B0-508B11A97C57Q36406975-6EBEA485-6849-4400-8106-2A7E2250EFB4Q36591360-CC4F681F-2247-40ED-8279-31467E991E53Q36900157-BD64B9B9-74B2-4552-B8CB-A3A999255279Q37974519-07A4CF91-0B3F-44CB-B25B-D03AFD115D17Q38970329-C3BF96EC-A211-49ED-9F22-BD0280FD6A3EQ40013180-E17A4238-D119-44D9-BB6A-15689AFAEECAQ40630645-94B156A0-AC3D-4685-A970-4BED4A35A9DBQ40658077-C63007ED-F894-4B10-AC21-F74BDC1C84C1Q40680262-62DCCB5A-AF51-4143-9996-B4DF7B849EABQ40680644-A7DA44BD-AFEF-4030-A95B-8EFE7189324CQ40917676-F1B70973-B8D2-41F4-8761-254461756874Q40947428-F35F38E9-CF0E-4AD4-9EF6-C5A9CB262237Q41269341-26A6716F-0643-4250-BBAE-A8239A409BD7
P2860
Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@en
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@nl
type
label
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@en
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@nl
prefLabel
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@en
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@nl
P2093
P356
P1476
Risk factors for fungal infect ...... rical therapy and prophylaxis.
@en
P2093
van 't Wout JW
P304
P356
10.1093/CLINIDS/18.4.525
P407
P577
1994-04-01T00:00:00Z